IDH1 and central nervous system cancer: Our current study is original since it employs a combination of three different, easily clinically transposable, PET radiotracers to investigate specific pathophysiological pathways of glioma development that may be uniquely impacted by the IDH1 mutation, using an innovative application of CRISPR/Cas9.